Immunoglobulin G (IgG) therapies are highly used to treat primary immune deficiency cause by the genetics. The demand for IgG has been increasing steadily for the last few years due to the increasing awareness of IgG therapy. The growth is also accounted for its new therapy for its newly identified indication. Based on controlled trials done by Network Meta Analysis (NMA), IgG therapy has been approved for the treatment of Guillain-Barré syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), and dermatomyositis. The Immunoglobulin G (IgG) therapies is also effective for the treatment of myasthenia gravis exacerbations and stiff-person syndrome. In addition, it provides convincing efficacy in autoimmune disorders like epilepsy, neuromyelitis, and autoimmune encephalitis.
A large proportion of IgG is used in specialties outside of immunology, such as oncology, neurology, hematology, and rheumatology. Compared to all, neurology is the fastest-growing specialty in the global market. The growth of the Immunoglobulin G market is attributed due to its approved for on-label use for chronic inflammatory demyelinating polyneuropathy (CIDP) followed by its off-label use in secondary immune deficiencies caused by lymphoma, myeloma, and leukemia and the certain immunosuppressive therapies esp. B-cell targeting therapies. Thus the wide range of IgG usage in multiple treatments for on-label and off-label prescription will continue to expand and drive IgG demand across the global market in the coming years.
The Middle East & Africa blood plasma derivatives market has been segmented into the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. Saudi Arabia is expected to account for the largest market share and is expected to boost moderately in the Middle East & Africa. The region has a significant prevalence of hemophilia, von Willebrand disease, and other bleeding disorders, increasing the adoption of plasma derivatives products for treatment. Furthermore, various partnerships between the market players and the government are also boosting the adoption of plasma derivatives for treatment boosting the market growth. For instance, in October 2021, Grifols and National Service Projects Organization (NSPO) Egypt inaugurated the first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines. This will enhance access to plasma products in the Middle East, Africa, and other countries boosting the market growth.
The Middle East & Africa blood plasma derivatives market is segmented into type, application, end user, and country.
The Middle East & Africa blood plasma derivatives market, by type, is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The immunoglobulins segment held a larger market share in 2022.
Based on application, the Middle East & Africa blood plasma derivatives market is divided into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand disease, and other applications. The immunodeficiency diseases applications segment held the largest share of the market in 2022.
The blood plasma derivatives market, by end user, is segmented into hospitals, diagnostic laboratories, clinics, and other end users. The hospitals segment held the largest share of the market in 2022.
Based on country, the Middle East & Africa blood plasma derivatives market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022.
Grifols SA; SK Plasma Co Ltd; Octapharma AG; Monobind Inc.; Intas Pharmaceuticals Ltd; CSL Behring LLC; LFB SA; Kedrion SpA; and Fusion Health Care Pvt Ltd are the leading companies operating in the Middle East & Africa blood plasma derivatives market.